Pharmacy

The FINANCIAL -- Merck on February 21 announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics, an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers by way of a scheme of arrangement (Scheme) for AUD 1.75 cash per Viralytics ...

More Articles ...

More Articles ...

The FINANCIAL -- Merck known as MSD outside the United States and Canada, on February 2 announced financial results for the fourth quarter and full year of ...

The FINANCIAL -- Roche and Flatiron Health, Inc. announced on February 15 that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, ...

The FINANCIAL -- Gilead Sciences, Inc. announced on February 6 its results of operations for the fourth quarter and full year ...